Mupirocine Biogaran (Mupirocin)

Mupirocin blocks bacterial isoleucyl‑tRNA synthetase, an enzyme required for protein synthesis. By preventing the incorporation of isoleucine into bacterial proteins, the drug halts bacterial growth and leads to cell death. This selective mechanism targets Gram‑positive organisms such as Staphylococcus aureus and Streptococcus pyogenes, providing effective topical antibacterial activity.

The dosage and frequency of Mupirocine Biogaran are determined by the prescribing healthcare professional based on the infection type, severity, and patient factors. Typically, a thin layer is applied to the affected area one to three times daily, but the exact regimen should follow the prescriber’s instructions and the product label.

Safety data for mupirocin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the need for treatment with their healthcare provider before using the product.

To order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Mupirocin is often compared with fusidic acid or bacitracin. Compared with fusidic acid, mupirocin has a broader spectrum against Staphylococcus aureus, including some methicillin‑resistant strains, and a lower risk of resistance when used appropriately. Unlike bacitracin, mupirocin is less associated with allergic contact dermatitis, making it a preferred choice for many clinicians.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct heat. Do not freeze the preparation. Keep the container tightly closed when not in use, and keep it out of reach of children. Follow any additional handling instructions on the label.

Apply a thin layer of the ointment to the cleaned, dry affected skin area using clean hands or a sterile applicator. The medication should be spread gently and allowed to dry. Avoid covering the treated area with airtight dressings unless directed by a clinician, as occlusion can increase systemic absorption.

Serious adverse reactions, though rare, include severe allergic contact dermatitis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and systemic hypersensitivity such as anaphylaxis. Patients should discontinue use and seek immediate medical attention if they develop widespread rash, blistering, swelling, or signs of an allergic reaction.

Individuals with a known hypersensitivity to mupirocin or any component of the formulation should avoid using the product. It is also contraindicated in patients with extensive skin disease where large surface area application is required, unless specifically advised by a physician. Neonates younger than two months should not receive the medication without specialist guidance.